Evaluation of HER2 protein overexpression in non-muscle invasive bladder cancer with emphasis on tumour grade and recurrence

Janane, A.; Hajji, F.; Ismail, T. Ould; Elondo, J.C.; Ghadouane, M.; Ameur, A.; Abbar, M.; Bouzidi, Abderrahmane Al

doi:10.1016/s2173-5786(11)70048-8

Cited by 5 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In keeping with these results, both Lim et al [51] and Chen et al [27], observed no HER2 amplification in lowgrade and/or low-stage tumors; on the other hand, highgrade (G3) NMIBCs share similarities in terms of the number of copies of HER2 and overexpression of the protein pointing to the equivalence [52,55]. Such findings lead to the hypothesis that HER2 amplification is an acquired oncogenetic phenomenon occurring chiefly in high-grade NMIBC, which is a genetically unstable neoplasm and that in such tumors it identifies those with a peculiarly adverse outcome [27,32].…”

Section: Association Of Clinical and Pathological Parameters With Hermentioning

confidence: 63%

“…First, the studies by Chen et al [27] and Lim et al [51] set a cutoff of HER2 overexpression by IHC at 50%, and the third one used the Hercept-test (cutoff 10%). As a consequence, one would consider the 50% cutoff as more suitable in NMIBC; however, the 10% cutoff has been extensively applied so far [34,[55][56][57][58], yielding significant results in terms of association between HER2 overexpression and recurrencefree survival (RFS) and/or progression-free survival (PFS). Furthermore, molecular mechanisms other than gene amplification account for HER2 protein overexpression in a considerable proportion of BCs [32,43,52,59].…”

Section: Issues In Her2 Assessment Methodsmentioning

confidence: 99%

“…Accordingly, Janane et al [55] found that HER2 expression was associated with lower RFS after BCG treatment. Other studies yielded conflicting results [96][97][98].…”

Section: Bcg Treatmentmentioning

confidence: 99%

“…To sum up, HER2 overexpression and/or amplification has been reported to be a predictor of RFS and/or PFS on univariate [27,34,51,55,56,67,92] and in a smaller number of studies on multivariate analysis [27,51,56,67] (Table 2).…”

Section: Survivalmentioning

confidence: 99%

See 3 more Smart Citations

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. A comprehensive review of the literature has been carried out. An electronic search of databases from PubMed, Scopus, Google Scholar was implemented. The search terms were: “BC,” “bladder carcinoma,” “bladder neoplasm,” “human epidermal growth factor 2,” “HER2,” “HER-2,” “c-erbB-2,” “c-erbB2,” “erbB-2,” “erbB2,” “neu,” “marker,” “biomarker,” and “prognosis”. Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC. HER2 stands out for being a prognostic factor as well as a therapeutic target in various cancers. Data from the literature concerning its use in BC provide conflicting results, probably due to the inherent complexity of BC biology. Efforts should be made to establish a suitable tumor-specific scoring system, and to assess single drugs’ efficacy in well-designed clinical trials.

show abstract

Section: Association Of Clinical and Pathological Parameters With Hermentioning

confidence: 63%

Section: Issues In Her2 Assessment Methodsmentioning

confidence: 99%

“…Accordingly, Janane et al [55] found that HER2 expression was associated with lower RFS after BCG treatment. Other studies yielded conflicting results [96][97][98].…”

Section: Bcg Treatmentmentioning

confidence: 99%

Section: Survivalmentioning

confidence: 99%

See 2 more Smart Citations

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry and FISH results were in closest agreement when overexpression was defined as 50% of tumor cells showing immunoreactivity. In another study of NMIBC, HER2 protein was overexpressed in 68.2% (30/44) of pT1GIII specimens and also predicted recurrence [47].…”

Section: Her2 Overexpression and Therapy In Bladder Cancermentioning

confidence: 93%

Targeting the Epidermal Growth Factor Receptor in Bladder Cancer

Weintraub¹

2013

J Carcinogene Mutagene

View full text Add to dashboard Cite

Erbb2 up‐regulation of ADAM12 expression accelerates skin cancer progression

Rao

Vogel

Yanagida

et al. 2014

Molecular Carcinogenesis

View full text Add to dashboard Cite

Solar ultraviolet (UV) radiation can cause severe damage to the skin and is the primary cause of most skin cancer. UV radiation causes DNA damage leading to mutations and also activates the Erbb2/HER2 receptor through indirect mechanisms involving reactive oxygen species. We hypothesized that Erbb2 activation accelerates the malignant progression of UV-induced skin cancer. Following the induction of benign squamous papillomas by UV exposure of v-ras(Ha) transgenic Tg.AC mice, mice were treated topically with the Erbb2 inhibitor AG825 and tumor progression monitored. AG825 treatment reduced tumor volume, increased tumor regression, and delayed the development of malignant squamous cell carcinoma (SCC). Progression to malignancy was associated with increased Erbb2 and ADAM12 (A Disintegin And Metalloproteinase 12) transcripts and protein, while inhibition of Erbb2 blocked the increase in ADAM12 message upon malignant progression. Similarly, human SCC and SCC cell lines had increased ADAM12 protein and transcripts when compared to normal controls. To determine whether Erbb2 up-regulation of ADAM12 contributed to malignant progression of skin cancer, Erbb2 expression was modulated in cultured SCC cells using forced over-expression or siRNA targeting, demonstrating up-regulation of ADAM12 by Erbb2. Furthermore, ADAM12 transfection or siRNA targeting revealed that ADAM12 increased both the migration and invasion of cutaneous SCC cells. Collectively, these results suggest Erbb2 up-regulation of ADAM12 as a novel mechanism contributing to the malignant progression of UV-induced skin cancer. Inhibition of Erbb2/HER2 reduced tumor burden, increased tumor regression, and delayed the progression of benign skin tumors to malignant SCC in UV-exposed mice. Inhibition of Erbb2 suppressed the increase in metalloproteinase ADAM12 expression in skin tumors, which in turn increased migration and tumor cell invasiveness.

show abstract

Evaluation of HER2 protein overexpression in non-muscle invasive bladder cancer with emphasis on tumour grade and recurrence

Cited by 5 publications

References 15 publications

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Targeting the Epidermal Growth Factor Receptor in Bladder Cancer

Erbb2 up‐regulation of ADAM12 expression accelerates skin cancer progression

Contact Info

Product

Resources

About